RAS Mutation clinical trials at UCSF

1 research study open to eligible people

Ras mutations are genetic changes that can lead to cancer. UCSF is researching DCC-3084 in people with advanced cancers linked to the MAPK pathway. This clinical trial looks at how the drug works on its own and with other treatment options.

Showing trials for

  • DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

    open to eligible people ages 18 years and up

    This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

    San Francisco, California and other locations

Our lead scientists for RAS Mutation research studies include .

Last updated: